AU2013246908B2 - Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors - Google Patents

Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors Download PDF

Info

Publication number
AU2013246908B2
AU2013246908B2 AU2013246908A AU2013246908A AU2013246908B2 AU 2013246908 B2 AU2013246908 B2 AU 2013246908B2 AU 2013246908 A AU2013246908 A AU 2013246908A AU 2013246908 A AU2013246908 A AU 2013246908A AU 2013246908 B2 AU2013246908 B2 AU 2013246908B2
Authority
AU
Australia
Prior art keywords
combination
compound
cushing
syndrome
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013246908A
Other languages
English (en)
Other versions
AU2013246908A1 (en
Inventor
Germo Hans GERICKE
Li Li
Mario Roberto MALDONADO LUTOMIRSKY
Herbert Anton SCHMID
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013246908A1 publication Critical patent/AU2013246908A1/en
Application granted granted Critical
Publication of AU2013246908B2 publication Critical patent/AU2013246908B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013246908A 2012-04-12 2013-04-10 Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors Ceased AU2013246908B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623117P 2012-04-12 2012-04-12
US61/623,117 2012-04-12
PCT/EP2013/057515 WO2013153129A1 (en) 2012-04-12 2013-04-10 Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

Publications (2)

Publication Number Publication Date
AU2013246908A1 AU2013246908A1 (en) 2014-10-23
AU2013246908B2 true AU2013246908B2 (en) 2016-06-30

Family

ID=48289057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013246908A Ceased AU2013246908B2 (en) 2012-04-12 2013-04-10 Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

Country Status (13)

Country Link
US (1) US9333234B2 (enExample)
EP (1) EP2836228B1 (enExample)
JP (1) JP6383352B2 (enExample)
KR (1) KR102136214B1 (enExample)
CN (1) CN104321074B (enExample)
AU (1) AU2013246908B2 (enExample)
BR (1) BR112014025058B1 (enExample)
CA (1) CA2869442C (enExample)
ES (1) ES2980806T3 (enExample)
IN (1) IN2014DN09240A (enExample)
MX (1) MX362533B (enExample)
RU (1) RU2663455C2 (enExample)
WO (1) WO2013153129A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041967T2 (hu) * 2010-01-14 2019-06-28 Novartis Ag Mellékvese hormon-módosító szer alkalmazása
HRP20181406T1 (hr) 2014-07-07 2018-10-19 Novartis Ag Farmaceutski dozni oblici
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
CA3011728A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088188A1 (en) * 2010-01-14 2011-07-21 Novartis Ag Use of an adrenal hormone-modifying agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2001157A3 (cs) * 1998-07-30 2002-02-13 Societe De Conseils De Recherches Et Dápplications Sloučenina a farmaceutický prostředek
PL368941A1 (en) * 2001-04-09 2005-04-04 The Administrators Of The Tulane Educational Fund Somatostatin agonists
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
US8575160B2 (en) * 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
WO2013131879A1 (en) * 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088188A1 (en) * 2010-01-14 2011-07-21 Novartis Ag Use of an adrenal hormone-modifying agent

Also Published As

Publication number Publication date
JP2015512923A (ja) 2015-04-30
KR102136214B1 (ko) 2020-07-22
US20150087588A1 (en) 2015-03-26
CA2869442A1 (en) 2013-10-17
US9333234B2 (en) 2016-05-10
MX2014012321A (es) 2015-09-24
AU2013246908A1 (en) 2014-10-23
EP2836228A1 (en) 2015-02-18
CN104321074A (zh) 2015-01-28
EP2836228B1 (en) 2024-03-20
RU2663455C2 (ru) 2018-08-06
BR112014025058B1 (pt) 2022-07-12
WO2013153129A1 (en) 2013-10-17
ES2980806T3 (es) 2024-10-03
RU2014145351A (ru) 2016-06-10
JP6383352B2 (ja) 2018-08-29
KR20150004831A (ko) 2015-01-13
IN2014DN09240A (enExample) 2015-07-10
CA2869442C (en) 2020-09-08
BR112014025058A2 (enExample) 2017-06-20
CN104321074B (zh) 2017-09-08
MX362533B (es) 2019-01-23

Similar Documents

Publication Publication Date Title
AU2013246908B2 (en) Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
EP2858631A1 (en) Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
CN118453597A (zh) 用于治疗非酒精性脂肪性肝病和非酒精性脂肪性肝炎的组合物
AU2019405771B2 (en) Methods for imaging and treatment of somatostatin-receptor positive tumors
US12280059B2 (en) Acyl-CoA synthetase 4 (ACSL4) inhibitory compound
Migeon et al. Adrenal cortex: hypo-and hyperfunction
Bhatti et al. Effects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism
EP4327825A1 (en) Therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance
Rieu et al. Paradoxical effect of somatostatin analogues on the ectopic secretion of corticotropin in two cases of small cell lung carcinoma
EP2224947B1 (en) Use of somatostatin analogs in meningioma
JP2020143037A (ja) 糖尿病合併心不全の治療用医薬組成物
Zotarelli Filho State-of-the-Art Clinical Results of Growth Hormone Secretagogues, SARM and Antagonists
KR20230060465A (ko) 장내 glp-1 분비 촉진 및 염증 완화 효능을 가지는 아젤라산 조성물
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
Mason 16th International Congress of Endocrinology/96th Annual Meeting and Exposition of the Endocrine Society (ICE/ENDO), Chicago, Illinois, USA-June 21-24, 2014

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired